drugset / Trial / NCT03669133

Vitamin E for NASH Treatment in HIV Infected Individuals

NCT03669133 ↗

Phase 2 Terminated 3 enrolled Indiana University
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to see how taking Vitamin E daily affects fatty liver in persons living with HIV. Subjects will have both HIV and a fatty liver and the purpose of the study is to learn if underlying liver condition (fatty liver) gets better, worse, or stays the same from taking Vitamin E.

Timeline

Start
2019-10-01
Primary completion
2021-03-08
Completion
2021-03-08

Outcome

Outcome not reported

Stopped: “lack of coordinator resources and lack of access to study resources during and due to the COVID pandemic”

Drugs

EvaluationDrugModalityDoseRoute
Comparator Vitamin E Other / unclassified 800 iu —